Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LGND files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLigand Pharmaceuticals stockholders approve stock plan amendment at annual meeting
Filed June 9, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
medium
Stockholders approved amendment and restatement of the 2002 Stock Incentive Plan, allowing continued equity compensation grants under updated terms with 95% support.
Item 5.07 verify on EDGAR → -
low
All eight director nominees elected to one-year terms expiring 2027, including Jason Aryeh, Todd Davis, Nancy Gray, Jason Haas, John Kozarich, John LaMattina, Stephen Sabba, and Martine Zimmermann.
Item 5.07 verify on EDGAR → -
low
Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 99% approval, continuing the firm's engagement.
Item 5.07 verify on EDGAR → -
low
Executive compensation approved in non-binding say-on-pay vote with 94% support, indicating shareholder satisfaction with management pay practices.
Item 5.07 verify on EDGAR →
Summary
Ligand Pharmaceuticals held its 2026 annual meeting on June 5, reporting routine governance outcomes. The most notable action was stockholder approval of amendments to the company's 2002 Stock Incentive Plan, which governs equity compensation for employees and directors.
The updated plan received strong support with 95% of votes cast in favor, suggesting shareholders are comfortable with management's approach to equity-based pay. All other proposals passed with similar margins. The full slate of eight directors was re-elected, Ernst & Young continues as auditor, and the advisory vote on executive compensation passed with 94% approval.
These results indicate no significant shareholder dissent on governance or compensation matters. For retail investors, this filing is purely procedural with no immediate business impact. The key item to monitor is how management uses the amended stock plan over the coming quarters—watch for any unusual acceleration in equity grants or changes to dilution rates in future proxy filings.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
At the Annual Meeting, the Company’s stockholders approved an amendment and restatement of the Company’s 2002 Stock Incentive Plan (the “2002 Plan”).
Stockholders voted to approve changes to the company's existing stock incentive plan at the June 5, 2026 annual meeting. The amended plan is now referred to as the Restated Plan. Details of the material terms were previously disclosed in the April 21, 2026 proxy statement.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Ligand Pharmaceuticals reported voting results from its 2026 annual meeting: all 8 directors elected, auditor ratified, executive compensation approved.
Added in current filing · verify on EDGAR →
Proposal 4. The approval of an amendment and restatement of the Company’s 2002 Stock Incentive Plan. In accordance with the results below, the proposal was approved.
Shareholders approved an amendment and restatement of the 2002 Stock Incentive Plan with 16,643,281 votes for and 870,556 against. This approval allows the company to continue granting equity-based compensation to employees and directors under updated plan terms.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In accordance with the results below, the selection of Ernst & Young LLP was ratified.
Shareholders ratified Ernst & Young LLP as the company's independent auditor for fiscal year 2026 with 18,526,515 votes for, 257,924 against, and 6,551 abstentions. This is a routine annual vote confirming the audit committee's auditor selection.
Added in current filing · verify on EDGAR →
Proposal 3. The approval of a non-binding advisory resolution regarding the compensation of the Company’s named executive officers. In accordance with the results below, the proposal was approved.
Shareholders approved the non-binding say-on-pay proposal with 16,497,712 votes for and 1,021,948 against. This advisory vote indicates shareholder support for the company's executive compensation practices, though it does not bind the board or compensation committee.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify